Objectives
To report and synthesize patterns of disease modifying agent (DMARD) use reported in observational studies of patients with established and early RA after the publication of ACR guidelines promoting universal DMARD use.
Methods
We searched PubMed for English-language full-length articles published between January 1, 2002, and October 1, 2012 that examined DMARD use. Data abstracted from articles included patient characteristics, country of study, time period studied, patient source, and treating physician type. Study quality was assessed using a modified Newcastle Ottawa Quality Assessment Scale.
Results
We reviewed 1287 abstracts; 98 full-length articles were selected for additional review, and 27 studies describing 28 cohorts of patients were included. Twelve studies described data from cohorts of patients with established RA, and DMARD use in this group of studies ranged from 73-100%. Five studies described data from patients sourced through administrative data demonstrated consistently lower DMARD use, ranging from 30-63%. Three studies conducted population-based surveys to define cases of RA where DMARD use ranged from 47-73%. Eight studies investigated patients with early RA. DMARD use among patients followed by rheumatologists ranged from 77-98% whereas DMARD use reported for patients seen by a mix of physicians was significantly lower (39-63%).
Conclusion
DMARD use in studies from RA cohorts or registries (in which patients were followed by rheumatologists) ranged from 73-100%, compared with 30-73% in studies from administrative data or population-based surveys (in which patients were not necessarily getting rheumatology subspecialty care).